Ex vivo and in vivo T-cell depletion in allogeneic transplantation: towards less or non-cytotoxic conditioning regimens

References

• Reisner Y, Kapoor N, Kirkpatrick D, et al. Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet. 1981 Aug 15 2(8242):327–331.
   PubMed Web of Science ®Google Scholar
• Reisner Y, Kapoor N, Kirkpatrick D, et al. Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood. 1983 Feb;61(2):341–348.
   PubMed Web of Science ®Google Scholar
• Friedrich W, Goldmann SF, Vetter U, et al. Immune reconstitution in severe combined immunodeficiency after transplantation of HLA-haploidentical, T-cell-depleted bone marrow. Lancet. 1984 Apr 7 1(8380):761–764.
   PubMed Web of Science ®Google Scholar
• Friedrich W, Goldmann SF, Ebell W, et al. Severe combined immunodeficiency: treatment by bone marrow transplantation in 15 infants using HLA-haploidentical donors. Eur J Pediatr. 1985 Jul;144(2):125–130.
   PubMed Web of Science ®Google Scholar
• Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998 Oct 22 339(17):1186–1193.
   PubMed Web of Science ®Google Scholar
• Henslee-Downey PJ, Parrish RS, MacDonald JS, et al. Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant. Transplantation. 1996 Mar 15 61(5):738–745.
   PubMed Web of Science ®Google Scholar
• Soiffer RJ, Mauch P, Fairclough D, et al. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Biol Blood Marrow Transplant. 1997 Apr;3(1):11–17.
   PubMedGoogle Scholar
• Körbling M, Przepiorka D, Huh YO, et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood. 1995 Mar 15 85(6):1659–1665.
   PubMed Web of Science ®Google Scholar
• Bensinger WI, Weaver CH, Appelbaum FR, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood. 1995 Mar 15 85(6):1655–1658.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Dreger P, Suttorp M, et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood. 1995 Mar 15 85(6):1666–1672.
   PubMed Web of Science ®Google Scholar
• Berenson RJ, Shpall EJ, Auditore-Hargreaves K, et al. Transplantation of CD34+ hematopoietic progenitor cells. Cancer Invest. 1996;14(6):589–596.
   PubMed Web of Science ®Google Scholar
• Reisner Y, Friedrich W, Fabian I. A shorter procedure for preparation E-rosette-depleted bone marrow for transplantation. Transplantation. 1986 Sep;42(3):312–315.
   PubMed Web of Science ®Google Scholar
• Miltenyi S, Müller W, Weichel W, et al. High gradient magnetic cell separation with MACS. Cytometry. 1990;11(2):231–238.
   PubMedGoogle Scholar
• Lang P, Schumm M, Taylor G, et al. Clinical scale isolation of highly purified peripheral CD34+progenitors for autologous and allogeneic transplantation in children. Bone Marrow Transplant. 1999 Sep;24(6):583–589.
   PubMed Web of Science ®Google Scholar
• Handgretinger R, Klingebiel T, Lang P, et al. Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant. 2001 Apr;27(8):777–783.
   PubMed Web of Science ®Google Scholar
• Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005 May 20 23(15):3447–3454.
   PubMed Web of Science ®Google Scholar
• Roldan E, Perales MA, Barba P. Allogeneic stem cell transplantation with CD34+ cell selection. Clin Hematol Int. 2019 Sep;1(3): 154–160.
   Google Scholar
• Huang YT, Neofytos D, Foldi J, et al. Cytomegalovirus infection after CD34(+)-selected hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016 Aug;22(8):1480–1486.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Huang YT, Kim SJ, et al. Adenovirus viremia in adult CD34(+) selected hematopoietic cell transplant recipients: low incidence and high clinical impact. Biol Blood Marrow Transplant. 2016 Jan;22(1):174–178.
   PubMed Web of Science ®Google Scholar
• Huang YT, Kim SJ, Lee YJ, et al. Co-infections by double-stranded DNA viruses after ex vivo T cell-depleted, CD34(+) selected hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2017 Oct;23(10):1759–1766.
   PubMed Web of Science ®Google Scholar
• Handgretinger R, Lang P, André MC. Exploitation of natural killer cells for the treatment of acute leukemia. Blood. 2016 Jun 30; 127(26):3341–3349.
   PubMed Web of Science ®Google Scholar
• Zuo W, Zhao X. Natural killer cells play an important role in virus infection control: antiviral mechanism, subset expansion and clinical application. Clin Immunol. 2021 Jun;227:108727.
   PubMed Web of Science ®Google Scholar
• Barfield RC, Otto M, Houston J, et al. A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation. Cytotherapy. 2004;6(1):1–6.
   PubMed Web of Science ®Google Scholar
• Chen X, Hale GA, Barfield R, et al. Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies. Br J Haematol. 2006 Nov;135(4):524–532.
   PubMed Web of Science ®Google Scholar
• Bader P, Soerensen J, Jarisch A, et al. Rapid immune recovery and low TRM in haploidentical stem cell transplantation in children and adolescence using CD3/CD19-depleted stem cells. Best Pract Res Clin Haematol. 2011 Sep;24(3):331–337.
   PubMed Web of Science ®Google Scholar
• Bethge WA, Haegele M, Faul C, et al. Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity. Exp Hematol. 2006 Dec;34(12):1746–1752.
   PubMed Web of Science ®Google Scholar
• Bethge WA, Faul C, Bornhäuser M, et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. Blood Cells Mol Dis. 2008 Jan-Feb;40(1):13–19.
   PubMed Web of Science ®Google Scholar
• Federmann B, Bornhauser M, Meisner C, et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study. Haematologica. 2012 Oct;97(10):1523–1531.
   PubMed Web of Science ®Google Scholar
• Wiercinska E, Seifried E, Bonig H. CD3/CD19 depletion for T-cell reduction of allogeneic transplants: mostly efficient, but not robust. Clin Hematol Int. 2021 Sep;3(3): 103–107.
   Google Scholar
• Vantourout P, Hayday A. Six-of-the-best: unique contributions of γδ T cells to immunology. Nat Rev Immunol. 2013 Feb;13(2):88–100.
   PubMed Web of Science ®Google Scholar
• Cela ME, Holladay MS, Rooney CM, et al. Gamma delta T lymphocyte regeneration after T lymphocyte-depleted bone marrow transplantation from mismatched family members or matched unrelated donors. Bone Marrow Transplant. 1996 Feb;17(2):243–247.
   PubMed Web of Science ®Google Scholar
• Minculescu L, Sengeløv H. The role of gamma delta T cells in haematopoietic stem cell transplantation. Scand J Immunol. 2015 Jun;81(6):459–468.
   PubMed Web of Science ®Google Scholar
• Lamb LS Jr., Henslee-Downey PJ, Parrish RS, et al. Increased frequency of TCR gamma delta + T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. J Hematother. 1996 Oct;5(5):503–509.
   Google Scholar
• Godder KT, Henslee-Downey PJ, Mehta J, et al. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant. 2007 Jun;39(12):751–757.
   PubMed Web of Science ®Google Scholar
• Chaleff S, Otto M, Barfield RC, et al. A large-scale method for the selective depletion of alphabeta T lymphocytes from PBSC for allogeneic transplantation. Cytotherapy. 2007. 9(8): 746–754.
   PubMed Web of Science ®Google Scholar
• Schumm M, Lang P, Bethge W, et al. Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device. Cytotherapy. 2013 Oct;15(10):1253–1258.
   PubMed Web of Science ®Google Scholar
• Bethge WA, Eyrich M, Mielke S, et al. Results of a multicenter phase I/II trial of TCRαβ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients. Bone Marrow Transplant. 2022 Mar;57(3):423–430.
   PubMed Web of Science ®Google Scholar
• de Witte M, Daenen LGM, van der Wagen L, et al. Allogeneic stem cell transplantation platforms with ex vivo and in vivo immune manipulations: count and adjust. Hemasphere. 2021 Jun;5(6):e580.
   PubMed Web of Science ®Google Scholar
• Dutt S, Tseng D, Ermann J, et al. Naive and memory T cells induce different types of graft-versus-host disease. J Immunol. 2007 Nov 15 179(10):6547–6554.
   PubMed Web of Science ®Google Scholar
• Chen BJ, Deoliveira D, Cui X, et al. Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse. Blood. 2007 Apr 1 109(7):3115–3123.
   PubMed Web of Science ®Google Scholar
• Bleakley M, Heimfeld S, Loeb KR, et al. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts. J Clin Invest. 2015 Jul 1 125(7):2677–2689.
   PubMed Web of Science ®Google Scholar
• Bleakley M, Sehgal A, Seropian S, et al. Naive T-cell depletion to prevent chronic graft-versus-host disease. J Clin Oncol. 2022 Apr 10;40(11):1174–1185.
   PubMed Web of Science ®Google Scholar
• Mamcarz E, Madden R, Qudeimat A, et al. Improved survival rate in T-cell depleted haploidentical hematopoietic cell transplantation over the last 15 years at a single institution. Bone Marrow Transplant. 2020 May;55(5):929–938.
   PubMed Web of Science ®Google Scholar
• Dunaikina M, Zhekhovtsova Z, Shelikhova L, et al. Safety and efficacy of the low-dose memory (CD45RA-depleted) donor lymphocyte infusion in recipients of αβ T cell-depleted haploidentical grafts: results of a prospective randomized trial in high-risk childhood leukemia. Bone Marrow Transplant. 2021 Jul;56(7):1614–1624.
   PubMed Web of Science ®Google Scholar
• Moirangthem RD, Ma K, Lizot S, et al. A DL-4- and TNFα-based culture system to generate high numbers of nonmodified or genetically modified immunotherapeutic human T-lymphoid progenitors. Cell Mol Immunol. 2021 Jul;18(7):1662–1676.
   PubMed Web of Science ®Google Scholar
• Muffly L, Sheehan K, Armstrong R, et al. Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation. Blood Adv. 2018 Mar 27 2(6):681–690.
   PubMed Web of Science ®Google Scholar
• Albon SJ, Mancao C, Gilmour K, et al. Optimization of methodology for production of CD25/CD71 allodepleted donor T cells for clinical use. Cytotherapy. 2013 Jan;15(1):109–121.
   PubMed Web of Science ®Google Scholar
• Zhou X, Dotti G, Krance RA, et al. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015 Jun 25 125(26):4103–4113.
   PubMed Web of Science ®Google Scholar
• Kaeuferle T, Krauss R, Blaeschke F, et al. Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation. J Hematol Oncol. 2019 Feb 6 12(1):13.
   PubMedGoogle Scholar
• Zhang P, Tey SK. Adoptive T cell therapy following haploidentical hematopoietic stem cell transplantation. Front Immunol. 2019;10:1854.
   PubMed Web of Science ®Google Scholar
• Hashimoto H, Kasteleiner P, Kressin J, et al. Removal of CD276(+) cells from haploidentical memory T-cell grafts significantly lowers the risk of GVHD. Bone Marrow Transplant. 2021 Oct;56(10):2336–2354.
   PubMed Web of Science ®Google Scholar
• Berenbaum MC, Brown IN. Prolongation of homograft survival in mice with single doses of cyclophosphamide. Nature. 1963 Oct 5; 200:84
   PubMed Web of Science ®Google Scholar
• Starzl TE, Halgrimson CG, Penn I, et al. Cyclophosphamide and human organ transplantation. Lancet. 1971 Jul 10 2(7715):70–74.
   PubMed Web of Science ®Google Scholar
• Luznik L, Jalla S, Engstrom LW, et al. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001 Dec 1;98(12):3456–3464.
   PubMed Web of Science ®Google Scholar
• Luznik L, O’Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008 Jun;14(6):641–650.
   PubMed Web of Science ®Google Scholar
• Symons HJ, Zahurak M, Cao Y, et al. Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. Blood Adv. 2020 Aug 25 4(16):3913–3925.
   PubMed Web of Science ®Google Scholar
• Mussetti A, Paviglianiti A, Parody R, et al. Is post-transplant cyclophosphamide the new methotrexate? J Clin Med. 2021 Aug 12;10(16). 10.3390/jcm10163548.
   PubMed Web of Science ®Google Scholar
• Mohty M. Mechanisms of action of antithymocyte globulin: t-cell depletion and beyond. Leukemia. 2007 Jul;21(7):1387–1394.
   PubMed Web of Science ®Google Scholar
• Bonifazi F, Rubio MT, Bacigalupo A, et al. Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. Bone Marrow Transplant. 2020 Jun;55(6):1093–1102.
   PubMed Web of Science ®Google Scholar
• Lv M, Chang YJ, Huang XJ. Update of the ”Beijing protocol” haplo-identical hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019 Aug;54(Suppl 2):703–707.
   PubMedGoogle Scholar
• Kanda J, Lopez RD, Rizzieri DA. Alemtuzumab for the prevention and treatment of graft-versus-host disease. Int J Hematol. 2011 May;93(5):586–593.
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000 Oct 1 96(7):2419–2425.
   PubMed Web of Science ®Google Scholar
• Buyck HC, Prentice HG, Griffiths PD, et al. The risk of early and late CMV DNAemia associated with Campath use in stem cell transplant recipients. Bone Marrow Transplant. 2010 Jul;45(7):1212–1219.
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002 Jun 15 99(12):4357–4363.
   PubMed Web of Science ®Google Scholar
• Admiraal R, Jol-van der Zijde CM, Furtado Silva JM, et al. Population pharmacokinetics of alemtuzumab (campath) in pediatric hematopoietic cell transplantation: towards individualized dosing to improve outcome. Clin Pharmacokinet. 2019 Dec;58(12):1609–1620.
   PubMed Web of Science ®Google Scholar
• Keogh SJ, Dalle JH, Admiraal R, et al. Serotherapy as graft-versus-host disease prophylaxis in haematopoietic stem cell transplantation for acute lymphoblastic leukaemia. Front Pediatr. 2021;9:805189.
   PubMed Web of Science ®Google Scholar
• Borst J, van Dongen JJM, de Vries E, et al. BMA031, a monoclonal antibody suited to identify the T-cell receptor αβ/CD3 complex on viable human T lymphocytes in normal and disease states. Hum Immunol. 1990 Nov;29(3):175–188.
   PubMed Web of Science ®Google Scholar
• Beelen DW, Grosse-Wilde H, Ryschka U, et al. Initial treatment of acute graft-versus-host disease with a murine monoclonal antibody directed to the human alpha/beta T cell receptor. Cancer Immunol Immunother. 1991;34(2):97–102.
   PubMed Web of Science ®Google Scholar
• Hebart H, Ehninger G, Schmidt H, et al. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies. Bone Marrow Transplantation. 1995 Jun;15(6):891–894.
   PubMed Web of Science ®Google Scholar
• Shearman CW, Pollock D, White G, et al. Construction, expression and characterization of humanized antibodies directed against the human alpha/beta T cell receptor. J Immunol. [1991 Dec 15];147(12):4366–4373.
   PubMed Web of Science ®Google Scholar
• Blank G, Welker C, Haarer J, et al. Selective, efficient modulation of activated CD4+ αβT cells by the novel humanized antibody GZ-αβTCR targeting human αβTCR. Bone Marrow Transplant. 2015 Mar;50(3):390–401.
   PubMed Web of Science ®Google Scholar
• Shultz LD, Lyons BL, Burzenski LM, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005 May 15 174(10):6477–6489.
   PubMed Web of Science ®Google Scholar
• Blank G, Welker C, Sipos B, et al. Preemptive administration of human αβ T cell receptor-targeting monoclonal antibody GZ-αβTCR potently abrogates aggressive graft-versus-host disease in vivo. Ann Hematol. 2015 Nov;94(11):1907–1919.
   PubMed Web of Science ®Google Scholar
• Handgretinger R, Koscielniak E, Niethammer D. Gene therapy for severe combined immunodeficiency disease. N Engl J Med. 2002 Aug 22;347(8):613–614. author reply 613-4.
   PubMed Web of Science ®Google Scholar
• Sarzotti-Kelsoe M, Win CM, Parrott RE, et al. Thymic output, T-cell diversity, and T-cell function in long-term human SCID chimeras. Blood. 2009 Aug 13 114(7):1445–1453.
   PubMed Web of Science ®Google Scholar
• Döring M, Cabanillas Stanchi KM, Feucht J, et al. Ferritin as an early marker of graft rejection after allogeneic hematopoietic stem cell transplantation in pediatric patients. Ann Hematol. 2016 Jan;95(2):311–323.
   PubMed Web of Science ®Google Scholar
• Schumm M, Feuchtinger T, Pfeiffer M, et al. Flow cytometry with anti HLA-antibodies: a simple but highly sensitive method for monitoring chimerism and minimal residual disease after HLA-mismatched stem cell transplantation. Bone Marrow Transplant. 2007 Jun;39(12):767–773.
   PubMed Web of Science ®Google Scholar
• Todd PA, Brogden RN. Muromonab CD3. A review of its pharmacology and therapeutic potential. Drugs. 1989 Jun;37(6):871–899.
   PubMed Web of Science ®Google Scholar
• Schober T, Magg T, Laschinger M, et al. A human immunodeficiency syndrome caused by mutations in CARMIL2. Nat Commun. 2017 Jan 23;8:14209.
   PubMed Web of Science ®Google Scholar
• Rastogi N, Thakkar D, Yadav SP. Successful allogeneic hematopoietic stem cell transplant for CARMIL2 deficiency. J Pediatr Hematol Oncol. 2021 Nov 1; 43(8):e1270–e1271.
   PubMed Web of Science ®Google Scholar
• Yonkof JR, Gupta A, Rueda CM, et al. A novel pathogenic variant in CARMIL2 (RLTPR) causing CARMIL2 deficiency and EBV-associated smooth muscle tumors. Front Immunol. 2020;11:884.
   PubMed Web of Science ®Google Scholar
• Colvin GA, Berz D, Ramanathan M, et al. Nonengraftment haploidentical cellular immunotherapy for refractory malignancies: tumor responses without chimerism. Biol Blood Marrow Transplant. 2009 Apr;15(4):421–431.
   PubMed Web of Science ®Google Scholar
• Kleinschmidt K, Lv M, Yanir A, et al. T-cell-replete versus ex vivo T-cell-depleted haploidentical haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia and other haematological malignancies. Front Pediatr. 2021;9:794541.
   PubMed Web of Science ®Google Scholar
• Stewart FM, Crittenden RB, Lowry PA, et al. Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice. Blood. 1993 May 15 81(10):2566–2571.
   PubMed Web of Science ®Google Scholar
• Stewart FM, Zhong S, Wuu J, et al. Lymphohematopoietic engraftment in minimally myeloablated hosts. Blood. 1998 May 15 91(10):3681–3687.
   PubMed Web of Science ®Google Scholar
• Quesenberry PJ, Stewart FM, Zhong S, et al. Lymphohematopoietic stem cell engraftment. Ann N Y Acad Sci. 1999 Apr 30;872(1 HEMATOPOIETIC):40–45. discussion 45-7.
   PubMedGoogle Scholar
• Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021 Jan 21 384(3):252–260.
   PubMed Web of Science ®Google Scholar
• Shapiro RM, Birch GC, Hu G, et al. Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. J Clin Invest. 2022 Jun 1;132(11). 10.1172/JCI154334.
   Web of Science ®Google Scholar
• Moscarelli J, Zahavi D, Maynard R, et al. The next generation of cellular immunotherapy: CAR-NK cells. Transplant Cell Ther. 2022 Jul 1;28(10):650–656.
   Google Scholar
• Handgretinger R, Schilbach K. The potential role of γδ T cells after allogeneic HCT for leukemia. Blood. 2018 Mar 8; 131(10):1063–1072.
   PubMed Web of Science ®Google Scholar
• Rozenbaum M, Meir A, Aharony Y, et al. Gamma-delta CAR-T cells show CAR-directed and independent activity against leukemia. Front Immunol. 2020;11:1347.
   PubMed Web of Science ®Google Scholar
• Ukrainskaya VM, Molostova O, Shelikhova L, et al. Haploidentical donor-derived memory CAR-T cells: first in human experience and in vitro correlative study. Blood Adv. 2022 Apr 21 6(19):5582–5588.
   PubMedGoogle Scholar
• Hartleif S, Lang P, Handgretinger R, et al. Outcomes of pediatric identical living-donor liver and hematopoietic stem cell transplantation. Pediatr Transplant. 2016 Nov;20(7):888–897.
   PubMed Web of Science ®Google Scholar
• Bertaina A, Grimm PC, Weinberg K, et al. Sequential stem cell-kidney transplantation in schimke immuno-osseous dysplasia. N Engl J Med. 2022 Jun 16 386(24):2295–2302.
   PubMed Web of Science ®Google Scholar